WAC 246-100-207
Human immunodeficiency virus (HIV)
testing -- Ordering -- Laboratory
screening -- Interpretation -- Reporting. (1) Except for persons
conducting seroprevalent studies under chapter 70.24 RCW, or
ordering or prescribing an HIV test for another individual
under subsections (4) and (5) of this section or under WAC 246-100-208(1), any person ordering or prescribing an HIV test
for another individual, shall:
(a) Obtain the informed consent of the individual,
separately or as part of the consent for a battery of other
routine tests provided that the individual is specifically
informed verbally or in writing that a test for HIV is
included; and
(b) Offer the individual an opportunity to ask questions
and decline testing; and
(c) If the HIV test is positive for or suggestive of HIV
infection, provide the name of the individual and locating
information to the local health officer for follow-up to
provide post-test counseling as required by WAC 246-100-209.
(2) The local and state health officer or authorized
representative shall periodically make efforts to inform
providers in their respective jurisdiction about the September
2006 Centers for Disease Control and Prevention "Revised
Recommendations for HIV Testing of Adults, Adolescents, and
Pregnant Women in Healthcare Settings."
(3) Health care providers may obtain a sample brochure
about the September 2006 Centers for Disease Control and
Prevention "Revised Recommendations for HIV Testing of Adults,
Adolescents, and Pregnant Women in Healthcare Settings" by
contacting the department's HIV prevention program at P.O. Box
47840, Olympia, WA 98504.
(4) Any person authorized to order or prescribe an HIV
test for another individual may offer anonymous HIV testing
without restriction.
(5) Blood banks, tissue banks, and others collecting or
processing blood, sperm, tissues, or organs for
transfusion/transplanting shall:
(a) Obtain or ensure informed specific consent of the
individual prior to ordering or prescribing an HIV test,
unless excepted under provisions in chapter 70.24 RCW;
(b) Explain that the reason for HIV testing is to prevent
contamination of the blood supply, tissue, or organ bank
donations;
(c) At the time of notification regarding a positive HIV
test, provide or ensure at least one individual counseling
session; and
(d) Inform the individual that the name of the individual
testing positive for HIV infection will be confidentially
reported to the state or local health officer.
(6) Persons subject to regulation under Title 48 RCW and
requesting an insured, subscriber, or potential insured or
subscriber to furnish the results of an HIV test for
underwriting purposes, as a condition for obtaining or
renewing coverage under an insurance contract, health care
service contract, or health maintenance organization agreement
shall:
(a) Before obtaining a specimen to perform an HIV test,
provide written information to the individual tested
explaining:
(i) What an HIV test is;
(ii) Behaviors placing a person at risk for HIV
infection;
(iii) The purpose of HIV testing in this setting is to
determine eligibility for coverage;
(iv) The potential risks of HIV testing; and
(v) Where to obtain HIV pretest counseling.
(b) Obtain informed specific written consent for an HIV
test. The written informed consent shall include:
(i) An explanation of confidential treatment of test
result reports limited to persons involved in handling or
determining applications for coverage or claims for the
applicant or claimant; and
(ii) That the name of the individual testing positive for
HIV infection will be confidentially reported to the state or
local health officer; and
(iii) At the time of notification regarding a positive
HIV test, provide or ensure at least one individual counseling
session.
(c) Establish procedures to inform an applicant of the
following:
(i) Post-test counseling specified under WAC 246-100-209
is required if an HIV test is positive or indeterminate;
(ii) Post-test counseling is done at the time any
positive or indeterminate HIV test result is given to the
tested individual;
(iii) The applicant is required to designate a health
care provider or health care agency to whom positive or
indeterminate HIV test results are to be provided for
interpretation and post-test counseling; and
(iv) When an individual applicant does not identify a
designated health care provider or health care agency and the
applicant's HIV test results are positive or indeterminate,
the insurer, health care service contractor, or health
maintenance organization shall provide the test results to the
state or local health department for interpretation and
post-test counseling.
(7) Laboratories and other places where HIV testing is
performed must demonstrate compliance with all of the
requirements in the Medical test site rules, chapter 246-338
WAC.
(8) The department laboratory quality assurance section
shall accept substitutions for enzyme immunoassay (EIA)
screening only as approved by the United States Food and Drug
Administration (FDA) and a published list or other written FDA
communication.
(9) Persons informing a tested individual of positive
laboratory test results indicating HIV infection shall do so
only when:
(a) The test or sequence of tests has been approved by
the FDA or the Federal Centers for Disease Control and
Prevention as a confirmed positive test result; and
(b) Such information consists of relevant facts
communicated in such a way that it will be readily understood
by the recipient.
(10) Persons may inform a tested individual of the
unconfirmed reactive results of an FDA-approved rapid HIV test
provided the test result is interpreted as preliminarily
positive for HIV antibodies, and the tested individual is
informed that:
(a) Further testing is necessary to confirm the reactive
screening test result;
(b) The meaning of reactive screening test result is
explained in simple terms, avoiding technical jargon;
(c) The importance of confirmatory testing is emphasized
and a return visit for confirmatory test results is scheduled;
and
(d) The importance of taking precautions to prevent
transmitting infection to others while awaiting results of
confirmatory testing is stressed.
[Statutory Authority: RCW 70.24.130. 10-01-082, §
246-100-207, filed 12/15/09, effective 1/15/10. Statutory
Authority: RCW 70.24.130 and 70.24.380. 05-11-110, §
246-100-207, filed 5/18/05, effective 6/18/05. Statutory
Authority: RCW 70.24.380. 02-12-106, § 246-100-207, filed
6/5/02, effective 7/6/02. Statutory Authority: RCW 70.24.125
and 70.24.130. 99-17-077, § 246-100-207, filed 8/13/99,
effective 9/1/99. Statutory Authority: RCW 70.24.380. 97-04-041, § 246-100-207, filed 1/31/97, effective 3/3/97. Statutory Authority: RCW 43.20.050 and 70.24.130. 92-02-019
(Order 225B), § 246-100-207, filed 12/23/91, effective
1/23/92. Statutory Authority: RCW 43.20.050. 91-02-051
(Order 124B), recodified as § 246-100-207, filed 12/27/90,
effective 1/31/91. Statutory Authority: Chapter 70.24 RCW
and RCW 70.24.130. 89-20-006 (Order 334), § 248-100-207,
filed 9/22/89, effective 10/23/89. Statutory Authority:
Chapter 70.24 RCW. 89-14-003 (Order 329), § 248-100-207,
filed 6/22/89; 88-17-058 (Order 318), § 248-100-207, filed
8/17/88.]